In addition, a significant reduction was observed in thepercentage of CD16+ NK cells in the presence of plasma-derivedexosomes of refractory/relapsed DLBCL patients in responsiveDLBCL patients (P=0.02) and healthy donors (P=0.0001). The gene discussed is FCGR3A; the disease is diffuse large B-cell lymphoma.